{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:20:30Z","timestamp":1792513230951,"version":"4.5.0"},"reference-count":160,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015763","name":"Leukaemia UK","doi-asserted-by":"publisher","award":["PG17\/002"],"award-info":[{"award-number":["PG17\/002"]}],"id":[{"id":"10.13039\/100015763","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015570","name":"Blood Cancer UK","doi-asserted-by":"publisher","award":["13042"],"award-info":[{"award-number":["13042"]}],"id":[{"id":"10.13039\/501100015570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015570","name":"Blood Cancer UK","doi-asserted-by":"publisher","award":["19004"],"award-info":[{"award-number":["19004"]}],"id":[{"id":"10.13039\/501100015570","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Biological Regulation"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jbior.2025.101119","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T05:58:33Z","timestamp":1758952713000},"page":"101119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Induced pluripotent stem cell-based modelling of disease evolution in myeloid leukemia: MDS to AML"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4330-2928","authenticated-orcid":false,"given":"Jacqueline","family":"Boultwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jbior.2025.101119_bib1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.jbior.2025.101119_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007705","article-title":"Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia","volume":"11","author":"Abdin","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.jbior.2025.101119_bib3","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.3390\/curroncol31050175","article-title":"A brief overview of the molecular landscape of myelodysplastic neoplasms","volume":"31","author":"Abdulbaki","year":"2024","journal-title":"Curr. Oncol."},{"issue":"7714","key":"10.1016\/j.jbior.2025.101119_bib4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","article-title":"Prediction of acute myeloid leukaemia risk in healthy individuals","volume":"559","author":"Abelson","year":"2018","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jbior.2025.101119_bib5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/hmg\/8.5.743","article-title":"Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA\/A)","volume":"8","author":"Allikmets","year":"1999","journal-title":"Hum. Mol. Genet."},{"issue":"11","key":"10.1016\/j.jbior.2025.101119_bib6","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2025.101119_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jbior.2017.09.008","article-title":"Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches","volume":"67","author":"Armstrong","year":"2018","journal-title":"Adv. Biol. Regul."},{"issue":"10","key":"10.1016\/j.jbior.2025.101119_bib8","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/bloodadvances.2021006325","article-title":"Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs","volume":"6","author":"Asimomitis","year":"2022","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.jbior.2025.101119_bib9","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.tcb.2022.12.001","article-title":"Clonal hematopoiesis and inflammation - the perpetual cycle","volume":"33","author":"Avagyan","year":"2023","journal-title":"Trends Cell Biol."},{"issue":"3","key":"10.1016\/j.jbior.2025.101119_bib10","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrm.2015.27","article-title":"Pluripotent stem cells in disease modelling and drug discovery","volume":"17","author":"Avior","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.jbior.2025.101119_bib11","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.3390\/ijms24065734","article-title":"The genetic landscape of myelodysplastic neoplasm progression to acute myeloid leukemia","volume":"24","author":"Banescu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.jbior.2025.101119_bib12","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2018-03-784116","article-title":"Chronic immune response dysregulation in MDS pathogenesis","volume":"132","author":"Barreyro","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jbior.2025.101119_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109809","article-title":"Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-Like disease to AML","volume":"27","author":"Barreyro","year":"2024","journal-title":"iScience"},{"issue":"26","key":"10.1016\/j.jbior.2025.101119_bib14","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.jbior.2025.101119_bib15","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood.V96.9.3256","article-title":"Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation","volume":"96","author":"Bekri","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jbior.2025.101119_bib16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood.2022018718","article-title":"Paralog-specific signaling by IRAK1\/4 maintains MyD88-independent functions in MDS\/AML","volume":"142","author":"Bennett","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbior.2025.101119_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MOH.0000000000000693","article-title":"IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies","volume":"29","author":"Bennett","year":"2022","journal-title":"Curr. Opin. Hematol."},{"issue":"15","key":"10.1016\/j.jbior.2025.101119_bib18","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.2023023727","article-title":"Molecular taxonomy of myelodysplastic syndromes and its clinical implications","volume":"144","author":"Bernard","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jbior.2025.101119_bib19","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.jbior.2025.101119_bib20","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.jbior.2025.101119_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101072","article-title":"Current landscape of translational and clinical research in myelodysplastic syndromes\/neoplasms (MDS): proceedings from the 1(st) international workshop on MDS (iwMDS) of the international consortium for MDS (icMDS)","volume":"60","author":"Bewersdorf","year":"2023","journal-title":"Blood Rev."},{"issue":"5","key":"10.1016\/j.jbior.2025.101119_bib22","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/leu.2010.20","article-title":"Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia","volume":"24","author":"Boultwood","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jbior.2025.101119_bib23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.stem.2018.01.011","article-title":"Clonal hematopoiesis and evolution to hematopoietic malignancies","volume":"22","author":"Bowman","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"5","key":"10.1016\/j.jbior.2025.101119_bib24","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1182\/blood-2002-07-2006","article-title":"Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia","volume":"101","author":"Cazzola","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbior.2025.101119_bib25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41392-024-01809-0","article-title":"Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications","volume":"9","author":"Cerneckis","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.jbior.2025.101119_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11912-015-0489-2","article-title":"Unraveling myelodysplastic syndromes: current knowledge and future directions","volume":"18","author":"Chamseddine","year":"2016","journal-title":"Curr. Oncol. Rep."},{"issue":"5","key":"10.1016\/j.jbior.2025.101119_bib27","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.stemcr.2018.03.020","article-title":"Dissecting the contributions of cooperating gene mutations to cancer phenotypes and drug responses with patient-derived iPSCs","volume":"10","author":"Chang","year":"2018","journal-title":"Stem Cell Rep."},{"issue":"2","key":"10.1016\/j.jbior.2025.101119_bib28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/MOH.0000000000000856","article-title":"Models to study myelodysplastic syndrome and acute myeloid leukaemia","volume":"32","author":"Chao","year":"2025","journal-title":"Curr. Opin. Hematol."},{"issue":"3","key":"10.1016\/j.jbior.2025.101119_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2016.11.018","article-title":"Human AML-iPSCs reacquire leukemic properties after differentiation and model clonal variation of disease","volume":"20","author":"Chao","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"8","key":"10.1016\/j.jbior.2025.101119_bib30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1182\/blood.2019004260","article-title":"Splicing factor mutations in hematologic malignancies","volume":"138","author":"Chen","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jbior.2025.101119_bib31","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.78136","article-title":"Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations","volume":"11","author":"Choudhary","year":"2022","journal-title":"eLife"},{"issue":"13","key":"10.1016\/j.jbior.2025.101119_bib32","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2021012652","article-title":"Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome","volume":"139","author":"Clough","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jbior.2025.101119_bib33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/bjh.13317","article-title":"Haematopoietic and immune defects associated with GATA2 mutation","volume":"169","author":"Collin","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.jbior.2025.101119_bib34","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"13","key":"10.1016\/j.jbior.2025.101119_bib35","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1084\/jem.20130751","article-title":"Gata2 is required for HSC generation and survival","volume":"210","author":"de Pater","year":"2013","journal-title":"J. Exp. Med."},{"issue":"13","key":"10.1016\/j.jbior.2025.101119_bib36","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jbior.2025.101119_bib37","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","article-title":"Somatic mutations precede acute myeloid leukemia years before diagnosis","volume":"24","author":"Desai","year":"2018","journal-title":"Nat. Med."},{"issue":"20","key":"10.1016\/j.jbior.2025.101119_bib38","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.3390\/cancers13205059","article-title":"Progress on Ras\/MAPK signaling research and targeting in blood and solid cancers","volume":"13","author":"Dillon","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.jbior.2025.101119_bib39","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jbior.2025.101119_bib40","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.jbior.2025.101119_bib41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jbior.2025.101119_bib42","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ncb3161","article-title":"Human definitive haemogenic endothelium and arterial vascular endothelium represent distinct lineages","volume":"17","author":"Ditadi","year":"2015","journal-title":"Nat. Cell Biol."},{"issue":"12","key":"10.1016\/j.jbior.2025.101119_bib43","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1038\/leu.2016.149","article-title":"Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes","volume":"30","author":"Dolatshad","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2025.101119_bib44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jbior.2018.10.001","article-title":"Application of induced pluripotent stem cell technology for the investigation of hematological disorders","volume":"71","author":"Dolatshad","year":"2019","journal-title":"Adv. Biol. Regul."},{"issue":"4","key":"10.1016\/j.jbior.2025.101119_bib45","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2643-3230.BCD-23-0041","article-title":"iPSC models of leukemia come of age","volume":"4","author":"Doulatov","year":"2023","journal-title":"Blood Cancer Discov."},{"issue":"1","key":"10.1016\/j.jbior.2025.101119_bib46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/MOH.0000000000000620","article-title":"Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells","volume":"28","author":"Doulatov","year":"2021","journal-title":"Curr. Opin. Hematol."},{"issue":"376","key":"10.1016\/j.jbior.2025.101119_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah5645","article-title":"Drug discovery for diamond-blackfan anemia using reprogrammed hematopoietic progenitors","volume":"9","author":"Doulatov","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.jbior.2025.101119_bib48","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.jbior.2025.101119_bib49","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage May no longer be optimal","volume":"139","author":"Estey","year":"2022","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.jbior.2025.101119_bib50","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1182\/blood-2013-02-453068","article-title":"How we treat lower-risk myelodysplastic syndromes","volume":"121","author":"Fenaux","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jbior.2025.101119_bib51","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6348","key":"10.1016\/j.jbior.2025.101119_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal2380","article-title":"Epigenetic plasticity and the hallmarks of cancer","volume":"357","author":"Flavahan","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jbior.2025.101119_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101056","article-title":"Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS","volume":"60","author":"Frumm","year":"2023","journal-title":"Blood Rev."},{"issue":"4","key":"10.1016\/j.jbior.2025.101119_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108326","article-title":"TET2-Loss-of-Function-Driven clonal hematopoiesis exacerbates experimental insulin resistance in aging and obesity","volume":"33","author":"Fuster","year":"2020","journal-title":"Cell Rep."},{"issue":"Suppl. 4","key":"10.1016\/j.jbior.2025.101119_bib55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajh.27659","article-title":"Emerging pathogenetic mechanisms and new drugs for anemia in myelofibrosis and myelodysplastic syndromes","volume":"100","author":"Gangat","year":"2025","journal-title":"Am. J. Hematol."},{"issue":"16_Suppl. l","key":"10.1016\/j.jbior.2025.101119_bib56","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1200\/JCO.2022.40.16_suppl.7016","article-title":"Phase 1\/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed\/refractory (R\/R) acute myeloid leukemia or lyelodysplastic syndrome","volume":"40","author":"Garcia-Manero","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.jbior.2025.101119_bib57","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","article-title":"Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia","volume":"145","author":"Gelsi-Boyer","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.jbior.2025.101119_bib58","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/stcltm\/szad022","article-title":"Reprogramming of acute myeloid leukemia patients cells: harboring cancer mutations requires targeting of AML hierarchy","volume":"12","author":"Golubeva","year":"2023","journal-title":"Stem Cells Transl. Med."},{"issue":"31","key":"10.1016\/j.jbior.2025.101119_bib59","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt Ostgard","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jbior.2025.101119_bib60","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6004\/jnccn.2017.0007","article-title":"Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Greenberg","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"12","key":"10.1016\/j.jbior.2025.101119_bib61","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jbior.2025.101119_bib62","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jbior.2025.101119_bib63","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s12015-023-10633-y","article-title":"Application of induced pluripotent stem cells in malignant solid tumors","volume":"19","author":"He","year":"2023","journal-title":"Stem. Cell Rev. Rep."},{"issue":"21","key":"10.1016\/j.jbior.2025.101119_bib64","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199905273402107","article-title":"Myelodysplasia","volume":"340","author":"Heaney","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.jbior.2025.101119_bib65","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.2951","article-title":"Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing","volume":"32","author":"Heckl","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"10.1016\/j.jbior.2025.101119_bib66","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.stem.2021.03.002","article-title":"Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNgamma signaling","volume":"28","author":"Hormaechea-Agulla","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/j.jbior.2025.101119_bib67","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1182\/blood.2018884338","article-title":"Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes","volume":"134","author":"Hsu","year":"2019","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jbior.2025.101119_bib68","doi-asserted-by":"crossref","first-page":"6078","DOI":"10.1182\/bloodadvances.2022007804","article-title":"RUNX1 deficiency cooperates with SRSF2 mutation to induce multilineage hematopoietic defects characteristic of MDS","volume":"6","author":"Huang","year":"2022","journal-title":"Blood Adv."},{"issue":"15","key":"10.1016\/j.jbior.2025.101119_bib69","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.2010.31.8576","article-title":"TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression","volume":"29","author":"Jadersten","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"6465","key":"10.1016\/j.jbior.2025.101119_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.jbior.2025.101119_bib71","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"149","key":"10.1016\/j.jbior.2025.101119_bib72","doi-asserted-by":"crossref","first-page":"149ra118","DOI":"10.1126\/scitranslmed.3004315","article-title":"Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia","volume":"4","author":"Jan","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"380","key":"10.1016\/j.jbior.2025.101119_bib73","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam9861","article-title":"From MDS\/AML to iPSC and back again","volume":"9","author":"Jonas","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.jbior.2025.101119_bib74","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.3390\/curroncol31040148","article-title":"Myelodysplastic neoplasms (MDS): the current and future treatment landscape","volume":"31","author":"Karel","year":"2024","journal-title":"Curr. Oncol."},{"issue":"7","key":"10.1016\/j.jbior.2025.101119_bib75","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jbior.2025.101119_bib76","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","article-title":"SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition","volume":"27","author":"Kim","year":"2015","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.jbior.2025.101119_bib77","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MOH.0000000000000567","article-title":"Driver mutations in acute myeloid leukemia","volume":"27","author":"Kishtagari","year":"2020","journal-title":"Curr. Opin. Hematol."},{"issue":"9","key":"10.1016\/j.jbior.2025.101119_bib78","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.stem.2021.08.002","article-title":"Human inducible pluripotent stem cells: realization of initial promise in drug discovery","volume":"28","author":"Kleiman","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"6","key":"10.1016\/j.jbior.2025.101119_bib79","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/blood-2017-01-762393","article-title":"Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice","volume":"131","author":"Kon","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jbior.2025.101119_bib80","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.jbior.2025.101119_bib81","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/2643-3230.BCD-22-0167","article-title":"Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of human acute myeloid leukemia","volume":"4","author":"Kotini","year":"2023","journal-title":"Blood Cancer Discov."},{"issue":"6","key":"10.1016\/j.jbior.2025.101119_bib82","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nbt.3178","article-title":"Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells","volume":"33","author":"Kotini","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.jbior.2025.101119_bib83","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.stem.2017.01.009","article-title":"Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia","volume":"20","author":"Kotini","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"5","key":"10.1016\/j.jbior.2025.101119_bib84","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.12203","article-title":"TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis","volume":"160","author":"Kulasekararaj","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.jbior.2025.101119_bib85","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1002\/stem.2655","article-title":"Brief report: human acute myeloid leukemia reprogramming to pluripotency is a rare event and selects for patient hematopoietic cells devoid of leukemic mutations","volume":"35","author":"Lee","year":"2017","journal-title":"Stem Cell."},{"issue":"8","key":"10.1016\/j.jbior.2025.101119_bib86","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/leu.2016.130","article-title":"'CHIP'ping away at clonal hematopoiesis","volume":"30","author":"Link","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jbior.2025.101119_bib87","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.88","article-title":"Autologous induced pluripotent stem cell-based cell therapies: promise, progress, and challenges","volume":"1","author":"Madrid","year":"2021","journal-title":"Curr. Protoc."},{"issue":"7","key":"10.1016\/j.jbior.2025.101119_bib88","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3390\/cancers13071746","article-title":"Epigenetics in a spectrum of myeloid diseases and its exploitation for therapy","volume":"13","author":"Maher","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.jbior.2025.101119_bib89","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.3742","article-title":"Dynamics of clonal evolution in myelodysplastic syndromes","volume":"49","author":"Makishima","year":"2017","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.jbior.2025.101119_bib90","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jbior.2025.101119_bib91","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood-2014-03-560227","article-title":"Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia","volume":"124","author":"Malcovati","year":"2014","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.jbior.2025.101119_bib92","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jbior.2025.101119_bib93","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.3324\/haematol.2015.127985","article-title":"Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia","volume":"100","author":"Meggendorfer","year":"2015","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.jbior.2025.101119_bib94","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3324\/haematol.2012.075325","article-title":"Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome","volume":"98","author":"Mian","year":"2013","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.jbior.2025.101119_bib95","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1097\/JS9.0000000000001892","article-title":"Unlocking the therapeutic potential: odyssey of induced pluripotent stem cells in precision cell therapies","volume":"110","author":"Mohite","year":"2024","journal-title":"Int. J. Surg."},{"issue":"4","key":"10.1016\/j.jbior.2025.101119_bib96","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.stemcr.2016.08.013","article-title":"Development refractoriness of MLL-rearranged human B cell acute leukemias to reprogramming into pluripotency","volume":"7","author":"Munoz-Lopez","year":"2016","journal-title":"Stem Cell Rep."},{"issue":"3","key":"10.1016\/j.jbior.2025.101119_bib97","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/leu.2016.251","article-title":"Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts","volume":"31","author":"Mupo","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.jbior.2025.101119_bib98","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","article-title":"Genetics of MDS","volume":"133","author":"Ogawa","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jbior.2025.101119_bib99","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.jbior.2025.101119_bib100","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.jbior.2025.101119_bib101","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.jbior.2025.101119_bib102","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbior.2025.101119_bib103","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41467-020-20440-5","article-title":"A logical network-based drug-screening platform for alzheimer's disease representing pathological features of human brain organoids","volume":"12","author":"Park","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.jbior.2025.101119_bib104","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.jbior.2025.101119_bib105","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood-2018-04-843771","article-title":"Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes\/pathways and clinical associations","volume":"132","author":"Pellagatti","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbior.2025.101119_bib106","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.12515","article-title":"The molecular pathogenesis of the myelodysplastic syndromes","volume":"95","author":"Pellagatti","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.jbior.2025.101119_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2022.100920","article-title":"Splicing factor mutations in the myelodysplastic syndromes: role of key aberrantly spliced genes in disease pathophysiology and treatment","volume":"87","author":"Pellagatti","year":"2023","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.jbior.2025.101119_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2024.101055","article-title":"Hyperactivation of NF-kappaB signaling in splicing factor mutant myelodysplastic syndromes and therapeutic approaches","volume":"95","author":"Pellagatti","year":"2025","journal-title":"Adv. Biol. Regul."},{"issue":"4","key":"10.1016\/j.jbior.2025.101119_bib109","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/leu.2010.31","article-title":"Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells","volume":"24","author":"Pellagatti","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jbior.2025.101119_bib110","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/leu.2015.129","article-title":"Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression","volume":"30","author":"Pellagatti","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jbior.2025.101119_bib111","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.3390\/cells10113250","article-title":"Induced pluripotent stem cells as a tool for modeling hematologic disorders and as a potential source for cell-based therapies","volume":"10","author":"Pratumkaew","year":"2021","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.jbior.2025.101119_bib112","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1084\/jem.20151775","article-title":"Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage","volume":"213","author":"Quek","year":"2016","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.jbior.2025.101119_bib113","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41576-019-0100-z","article-title":"Induced pluripotent stem cells in disease modelling and drug discovery","volume":"20","author":"Rowe","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jbior.2025.101119_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2024.104669","article-title":"Inducible pluripotent stem cell models to study bone marrow failure and MDS predisposition syndromes","volume":"143","author":"Sahoo","year":"2025","journal-title":"Exp. Hematol."},{"issue":"2","key":"10.1016\/j.jbior.2025.101119_bib115","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ame2.12165","article-title":"Cancer models in preclinical research: a chronicle review of advancement in effective cancer research","volume":"4","author":"Sajjad","year":"2021","journal-title":"Animal Model. Exp. Med."},{"issue":"3","key":"10.1016\/j.jbior.2025.101119_bib116","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","article-title":"Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes","volume":"30","author":"Sallman","year":"2016","journal-title":"Leukemia"},{"issue":"7531","key":"10.1016\/j.jbior.2025.101119_bib117","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature13906","article-title":"Rapid modelling of cooperating genetic events in cancer through somatic genome editing","volume":"516","author":"Sanchez-Rivera","year":"2014","journal-title":"Nature"},{"issue":"8041","key":"10.1016\/j.jbior.2025.101119_bib118","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-Mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.jbior.2025.101119_bib119","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/sj.leu.2401084","article-title":"Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome","volume":"12","author":"Sato","year":"1998","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jbior.2025.101119_bib120","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nm.4047","article-title":"Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9","volume":"22","author":"Schneider","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbior.2025.101119_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1236553","article-title":"Functional genomics in stem cell models: considerations and applications","volume":"11","author":"Shevade","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"issue":"2","key":"10.1016\/j.jbior.2025.101119_bib122","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrd.2016.245","article-title":"Induced pluripotent stem cell technology: a decade of progress","volume":"16","author":"Shi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.jbior.2025.101119_bib123","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc3343","article-title":"The role of mutations in epigenetic regulators in myeloid malignancies","volume":"12","author":"Shih","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.jbior.2025.101119_bib124","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ccell.2015.03.009","article-title":"Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia","volume":"27","author":"Shih","year":"2015","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jbior.2025.101119_bib125","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1038\/s41467-018-06063-x","article-title":"Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia","volume":"9","author":"Shiozawa","year":"2018","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.jbior.2025.101119_bib126","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1242\/dev.125.7.1207","article-title":"The additional sex combs gene of drosophila encodes a chromatin protein that binds to shared and unique polycomb group sites on polytene chromosomes","volume":"125","author":"Sinclair","year":"1998","journal-title":"Development"},{"issue":"9","key":"10.1016\/j.jbior.2025.101119_bib127","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1038\/s41375-020-0753-9","article-title":"SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications","volume":"34","author":"Singh","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jbior.2025.101119_bib128","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41556-019-0314-5","article-title":"U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies","volume":"21","author":"Smith","year":"2019","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.jbior.2025.101119_bib129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbior.2025.101119_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101128","article-title":"Classification, risk stratification and response assessment in myelodysplastic syndromes\/neoplasms (MDS): a state-of-the-art report on behalf of the international consortium for MDS (icMDS)","volume":"62","author":"Stahl","year":"2023","journal-title":"Blood Rev."},{"issue":"7","key":"10.1016\/j.jbior.2025.101119_bib131","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.mayocp.2015.04.001","article-title":"Myelodysplastic syndromes: diagnosis and treatment","volume":"90","author":"Steensma","year":"2015","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.jbior.2025.101119_bib132","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbior.2025.101119_bib133","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2015-07-604538","article-title":"Emerging therapeutic drugs for AML","volume":"127","author":"Stein","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jbior.2025.101119_bib134","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood.2021015162","article-title":"Inflammation and myeloid malignancy: quenching the flame","volume":"140","author":"Stubbins","year":"2022","journal-title":"Blood"},{"issue":"7655","key":"10.1016\/j.jbior.2025.101119_bib135","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nature22370","article-title":"Haematopoietic stem and progenitor cells from human pluripotent stem cells","volume":"545","author":"Sugimura","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jbior.2025.101119_bib136","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jbior.2025.101119_bib137","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.jbior.2025.101119_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2023.100993","article-title":"Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies","volume":"91","author":"Tatwavedi","year":"2024","journal-title":"Adv. Biol. Regul."},{"issue":"19","key":"10.1016\/j.jbior.2025.101119_bib139","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"5391","key":"10.1016\/j.jbior.2025.101119_bib140","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1126\/science.282.5391.1145","article-title":"Embryonic stem cell lines derived from human blastocysts","volume":"282","author":"Thomson","year":"1998","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.jbior.2025.101119_bib141","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201544","article-title":"Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS","volume":"218","author":"Trowbridge","year":"2021","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.jbior.2025.101119_bib142","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.3390\/ijms22095013","article-title":"The impact of epigenetic modifications in myeloid malignancies","volume":"22","author":"Venney","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.jbior.2025.101119_bib143","first-page":"283","article-title":"Pathogenesis and inflammaging in myelodysplastic syndrome","volume":"110","author":"Villaume","year":"2025","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.jbior.2025.101119_bib144","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1182\/blood-2014-10-570234","article-title":"De novo generation of HSCs from somatic and pluripotent stem cell sources","volume":"125","author":"Vo","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jbior.2025.101119_bib145","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.jbior.2025.101119_bib146","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.stem.2021.01.011","article-title":"Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets","volume":"28","author":"Wang","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"10","key":"10.1016\/j.jbior.2025.101119_bib147","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.3324\/haematol.2015.127092","article-title":"GATA2 and secondary mutations in familial myelodysplastic syndromes and pediatric myeloid malignancies","volume":"100","author":"Wang","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jbior.2025.101119_bib148","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.stem.2022.02.009","article-title":"3D-organoid culture supports differentiation of human CAR(+) iPSCs into highly functional CAR T cells","volume":"29","author":"Wang","year":"2022","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/j.jbior.2025.101119_bib149","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jbior.2025.101119_bib150","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-21-0508","article-title":"Integrative RNA-Omics discovers GNAS alternative splicing as a phenotypic driver of splicing factor-mutant neoplasms","volume":"12","author":"Wheeler","year":"2022","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.jbior.2025.101119_bib151","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1158\/0008-5472.CAN-13-2971","article-title":"Cancer cell lines for drug discovery and development","volume":"74","author":"Wilding","year":"2014","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.jbior.2025.101119_bib152","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ccr.2014.03.036","article-title":"Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo","volume":"25","author":"Woll","year":"2014","journal-title":"Cancer Cell"},{"issue":"19","key":"10.1016\/j.jbior.2025.101119_bib153","doi-asserted-by":"crossref","DOI":"10.1242\/dev.203090","article-title":"Manipulating cell fate through reprogramming: approaches and applications","volume":"151","author":"Yagi","year":"2024","journal-title":"Development"},{"issue":"7367","key":"10.1016\/j.jbior.2025.101119_bib154","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.jbior.2025.101119_bib155","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1182\/blood.2021012519","article-title":"Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation","volume":"139","author":"You","year":"2022","journal-title":"Blood"},{"issue":"5858","key":"10.1016\/j.jbior.2025.101119_bib156","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1126\/science.1151526","article-title":"Induced pluripotent stem cell lines derived from human somatic cells","volume":"318","author":"Yu","year":"2007","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jbior.2025.101119_bib157","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.stem.2016.08.021","article-title":"Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia","volume":"19","author":"Zambetti","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"5","key":"10.1016\/j.jbior.2025.101119_bib158","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/bjh.14305","article-title":"Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes","volume":"175","author":"Zeidan","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.jbior.2025.101119_bib159","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.3390\/ijms25052680","article-title":"Application prospect of induced pluripotent stem cells in organoids and cell therapy","volume":"25","author":"Zhang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jbior.2025.101119_bib160","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/bioengineering12010060","article-title":"iPSC technology revolutionizes CAR-T cell therapy for cancer treatment","volume":"12","author":"Zong","year":"2025","journal-title":"Bioengineering (Basel)"}],"container-title":["Advances in Biological Regulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492625000466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492625000466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:35:40Z","timestamp":1781076940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212492625000466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":160,"alternative-id":["S2212492625000466"],"URL":"https:\/\/doi.org\/10.1016\/j.jbior.2025.101119","relation":{},"ISSN":["2212-4926"],"issn-type":[{"value":"2212-4926","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induced pluripotent stem cell-based modelling of disease evolution in myeloid leukemia: MDS to AML","name":"articletitle","label":"Article Title"},{"value":"Advances in Biological Regulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbior.2025.101119","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101119"}}